RxDoctor Payments Data

Matthew O Hern, MD

Interventional Cardiology · Liverpool, NYNPI 1821098625

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 129 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Abiomed$308
  • Pfizer$160
  • Abbott$153
  • Novartis$124
  • Johnson & Johnson$117
  • plus $533 from 10 others

What the payments were for

  • Food & beverage$2,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,582 in reported general payments places this provider in the 20th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$122,479
Medicare patients
317
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$100,167
JardianceEmpagliflozin54$76,492
EntrestoSacubitril/Valsartan32$42,584
XareltoRivaroxaban35$38,731
MultaqDronedarone Hcl12$22,267
Repatha SureclickEvolocumab20$18,434
Metoprolol Succinate221$2,925
Atorvastatin Calcium224$2,132
Ranolazine ErRanolazine16$1,732
Eplerenone12$1,556
Bisoprolol Fumarate58$1,381
Ezetimibe61$1,183
Isosorbide Mononitrate ErIsosorbide Mononitrate83$1,142
ClopidogrelClopidogrel Bisulfate132$959
Rosuvastatin Calcium50$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$100,16796 claims
Boehringer IngelheimJardiance$76$76,49254 claims
NovartisEntresto$124$42,58432 claims
Johnson & JohnsonXarelto$117$38,73135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →